Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation

Abstract Epithelioid glioblastoma (eGB), a very aggressive and rare brain tumour, is associated with a dismal median overall survival. Effective therapies for patients with eGB, particularly with leptomeningeal dissemination, are still lacking. Here, we describe a case of a 25-year-old male diagnose...

Full description

Bibliographic Details
Main Authors: J. Steininger, C. Buszello, R. Oertel, M. Meinhardt, S. Schmid, K. Engellandt, S. Herold, S. Stasik, A. Ebrahimi, B. Renner, C. Thiede, I.Y. Eyüpoglu, G. Schackert, S. Beissert, F. Meier, J. Radke, D. Westphal, T. A. Juratli
Format: Article
Language:English
Published: BMC 2024-08-01
Series:Acta Neuropathologica Communications
Subjects:
Epithelioid glioblastoma
BRAF mutation
MAPK inhibitors
Leptomeningeal disease
Online Access:https://doi.org/10.1186/s40478-024-01834-8

Internet

https://doi.org/10.1186/s40478-024-01834-8

Similar Items